# Fall in heart pumping function (ejection fraction) on HER2-targeted drugs: scans and the hold, restart and stop rules by product

Source: https://onco.cc/protocols/left-ventricular-dysfunction-on-her2-targeted-drugs/  
OnCo record `left-ventricular-dysfunction-on-her2-targeted-drugs` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Trastuzumab and other HER2-targeted drugs can weaken the heart's pumping, so your team scans your heart before and during treatment. If the pumping measure (ejection fraction) falls past a set line, the drug is usually paused, the scan repeated in 3 to 4 weeks, and treatment restarted if it recovers. The lines differ by drug and country. Report new breathlessness or ankle swelling straight away.

## Summary

Each HER2-targeted product's label sets its own rule for a fall in left ventricular ejection fraction (LVEF), and the rules differ between products and, for trastuzumab and lapatinib, between the US and EU texts. Trastuzumab, US label: LVEF before treatment, every 3 months during and at the end, and every 6 months for at least 2 years after adjuvant treatment; withhold for at least 4 weeks for an absolute fall of 16 points or more, or an LVEF below the institution's normal limit with a fall of 10 points or more; it may be resumed if within 4 to 8 weeks LVEF is back within normal limits and no more than 15 points below baseline; permanently discontinue for a fall lasting more than 8 weeks or more than 3 suspensions. Trastuzumab, EU SmPC: suspend for a fall of 10 points or more to below 50 per cent, repeat LVEF within about 3 weeks, and strongly consider discontinuation if it has not improved or symptomatic heart failure has developed, unless the benefit outweighs the risk; refer to a cardiologist. Pertuzumab with trastuzumab (US and EU, and the fixed-dose subcutaneous combination): withhold for at least 3 weeks in metastatic disease for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 50 per cent with a fall of 10 points or more. Trastuzumab emtansine (US and EU): in metastatic disease withhold for LVEF below 40 per cent, or 40 to 45 per cent with a fall of 10 points or more; in early breast cancer for LVEF below 45 per cent, or 45 to 49 per cent with a fall of 10 points or more; repeat within about 3 weeks. Trastuzumab deruxtecan (US and EU): interrupt for LVEF 40 to 45 per cent with a fall of 10 to 20 points, for LVEF below 40 per cent or for a fall of more than 20 points; repeat within 3 weeks; permanently discontinue if the lower line is confirmed or for symptomatic heart failure. Zanidatamab (US and EU) and margetuximab (US) follow the 16-point and 10-point pattern of US trastuzumab, with 50 per cent as the limit (for margetuximab, where the institution has no normal limit of its own). Lapatinib: discontinue for a Grade 2 or greater LVEF decrease (US) or grade 3 or greater symptoms (EU), or LVEF below the lower limit of normal; it may be restarted at a reduced dose after at least 2 weeks if LVEF is normal and there are no symptoms.

The 2022 ESC guideline grades by severity instead. It recommends temporary interruption for moderate or severe symptomatic dysfunction (Class I, Level C, with heart failure therapy at Class I, Level B) and temporary interruption with heart failure therapy for a new asymptomatic LVEF below 40 per cent (Class I, Level C); says continuation should be considered with a new asymptomatic LVEF of 40 to 49 per cent with more frequent monitoring (Class IIa, Level B), with an ACE inhibitor or ARB and a beta-blocker (Class I, Level C); and says, in a footnote with no grade of its own, that resumption should be considered once LVEF is 40 per cent or more and symptoms have gone. ESMO (2020) is close to ESC. So a person with an asymptomatic LVEF in the 40s can fall on the hold side of a label and on the consider-continuing side of the guideline. Two small single-arm studies continued treatment on heart medicines: SAFE-HEaRt (31 patients with an LVEF of 40 to 49 per cent, supported by Genentech) and SCHOLAR (20 patients with an LVEF between 40 per cent and the lower limit of normal, or a fall of 15 points or more); in each, 1 in 10 had a cardiac event or a further marked fall. This page explains care; the treating team's own protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: LVEF decline on trastuzumab; trastuzumab cardiotoxicity hold rules; left ventricular dysfunction on pertuzumab; ejection fraction fall on trastuzumab emtansine; ejection fraction fall on trastuzumab deruxtecan; HER2 therapy cardiac dysfunction; when to stop trastuzumab for the heart
- Tags: protocol; cardio-oncology; her2

## Connected records

- technologies: [Cardio-oncology](https://onco.cc/technologies/cardio-oncology/)
- protocols: [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [Heart scans after anthracyclines or chest radiotherapy for cancer in childhood, adolescence or young adulthood](https://onco.cc/protocols/cardiomyopathy-surveillance-after-childhood-cancer/), [Immune-related myocarditis from checkpoint inhibitors](https://onco.cc/protocols/irae-myocarditis/)
- fronts: [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- drugs: [Lapatinib](https://onco.cc/drugs/lapatinib/), [Margetuximab](https://onco.cc/drugs/margetuximab/), [Pertuzumab](https://onco.cc/drugs/pertuzumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/)
- institutions: [European Medicines Agency](https://onco.cc/institutions/ema/), [European Society for Medical Oncology (ESMO)](https://onco.cc/institutions/esmo/)
- terms: [Cardiotoxicity (LVEF decline, cardiomyopathy)](https://onco.cc/terms/cardiotoxicity/), [Trastuzumab cardiotoxicity](https://onco.cc/terms/trastuzumab-cardiotoxicity/)
- key papers: [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://onco.cc/key-papers/paper-lyon-eur-heart-j/)

---
JSON: https://onco.cc/api/v1/entities/left-ventricular-dysfunction-on-her2-targeted-drugs.json